Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and
receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed
AML.